Transient neonatal myasthenia gravis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:391504P94.0
Who is this for?
Show terms as
10FDA treatments15Specialists8Treatment centers5Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Transient neonatal myasthenia gravis (also called transient neonatal MG) is a temporary condition that affects newborn babies born to mothers who have myasthenia gravis. Myasthenia gravis is an autoimmune disease where the mother's immune system makes antibodies that attack the connections between nerves and muscles. During pregnancy, these antibodies can cross the placenta and enter the baby's bloodstream. After birth, these maternal antibodies cause the baby to have muscle weakness and difficulty with basic functions like feeding, breathing, and moving. The most common symptoms include a weak cry, poor sucking and feeding ability, general floppiness (low muscle tone), and sometimes breathing difficulties. The baby may also have a less expressive face and reduced movement of the arms and legs. Symptoms usually appear within the first few hours to days after birth. The good news is that this condition is temporary. As the mother's antibodies naturally break down and leave the baby's body over the first few weeks of life, the symptoms gradually improve and eventually go away completely. Treatment is supportive and may include help with feeding, breathing support if needed, and sometimes medications like anticholinesterase drugs (such as pyridostigmine or neostigmine) to temporarily improve muscle strength. Most babies recover fully within two to four weeks, though some may take up to a few months. The condition does not come back once it resolves, and the child's long-term development is typically normal.

Also known as:

Key symptoms:

Weak or feeble cryPoor sucking and difficulty feedingGeneral floppiness or low muscle toneBreathing difficultiesReduced facial expressionsDecreased movement of arms and legsDrooping eyelidsDifficulty swallowingNeed for breathing supportWeak grasp reflex

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

FDA & Trial Timeline

7 events
Jan 2026ZILBRYSQ: New indication approved
FDAcompleted
Apr 2025Imaavy: FDA approved

treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive

FDAcompleted
Oct 2023Zilbrysq: FDA approved

Treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive

FDAcompleted
Jun 2023Rystiggo: FDA approved

treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive

FDAcompleted
Jun 2023Vyvgart Hytrulo: FDA approved

treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive

FDAcompleted
Dec 2021Vyvgart: FDA approved

treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive

FDAcompleted
Oct 2017

SOLIRIS: FDA approved

for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

10 available

BKEMV

ECULIZUMAB-AEEB· Amgen Inc■ Boxed Warning

The treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

Uplizna

INEBILIZUMAB· Horizon Therapeutics USA, Inc.

indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive

EPYSQLI

ECULIZUMAB-AAGH· Teva Pharmaceuticals USA, Inc.■ Boxed Warning

the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive

Ultomiris

RAVULIZUMAB· Alexion Pharmaceuticals Inc.■ Boxed Warning

the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive

Imaavy

NIPOCALIMAB· Janssen Biotech, Inc.Orphan Drug
treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) ant

treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive

Zilbrysq

ZILUCOPLAN· UCB, Inc.■ Boxed WarningOrphan Drug

Treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive

Rystiggo

ROZANOLIXIZUMAB· UCB, Inc.Orphan Drug

treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive

Vyvgart Hytrulo

EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT)· argenx USOrphan Drug

treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive

Vyvgart

EFGARTIGIMOD ALFA· argenx USOrphan Drug

treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive

SOLIRIS

ECULIZUMAB· Alexion Pharmaceuticals Inc.■ Boxed WarningOrphan Drug

for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive

No actively recruiting trials found for Transient neonatal myasthenia gravis at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Transient neonatal myasthenia gravis community →

Specialists

15 foundView all specialists →
SR
Sanja Ristovska
Specialist
1 Transient neonatal myasthenia gravis publication
OS
Orhideja Stomnaroska
Specialist
1 Transient neonatal myasthenia gravis publication
RD
Renata Dimitrioska
Specialist
1 Transient neonatal myasthenia gravis publication
JL
Jenny Linnea Victoria Lindroos
Specialist
1 Transient neonatal myasthenia gravis publication
MB
Marte-Helene Bjørk
Specialist
1 Transient neonatal myasthenia gravis publication
NG
Nils Erik Gilhus
Specialist
1 Transient neonatal myasthenia gravis publication
CG
Catarina Santiago Gonçalves
Specialist
1 Transient neonatal myasthenia gravis publication
MM
M Ines Nunes Marques
Specialist
1 Transient neonatal myasthenia gravis publication
SA
Sónia Antunes
Specialist
1 Transient neonatal myasthenia gravis publication
AS
Ana Serrano
Specialist
1 Transient neonatal myasthenia gravis publication
RS
Robert E Schumacher
Specialist
1 Transient neonatal myasthenia gravis publication
JY
Jinrong Yang
Specialist
1 Transient neonatal myasthenia gravis publication
LP
Liping Pan
Specialist
1 Transient neonatal myasthenia gravis publication
PK
Paramjeet K Kochhar
ANN ARBOR, MI
Specialist
1 Transient neonatal myasthenia gravis publication
SS
Subrata Sarkar
ANN ARBOR, MI
Specialist
1 Transient neonatal myasthenia gravis publication

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

5 resources
BKEMV(ECULIZUMAB-AEEB)Amgen Inc
Uplizna(INEBILIZUMAB)Horizon Therapeutics USA, Inc.
Zilbrysq(ZILUCOPLAN)UCB, Inc.
Rystiggo(ROZANOLIXIZUMAB)UCB, Inc.
SOLIRIS(ECULIZUMAB)Alexion Pharmaceuticals Inc.

Travel Grants

No travel grants are currently matched to Transient neonatal myasthenia gravis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Transient neonatal myasthenia gravisForum →

No community posts yet. Be the first to share your experience with Transient neonatal myasthenia gravis.

Start the conversation →

Latest news about Transient neonatal myasthenia gravis

1 articles
NewsDIAGNOSTICS (BASEL, SWITZERLAND)Mar 28, 2026
Myasthenia Gravis in Pregnancy: Prenatal and Postnatal Diagnostic Challenges-A Narrative Review.
Myasthenia gravis (MG) is a prevalent autoimmune disorder affecting neuromuscular junctions, typically characterized by muscle weakness due to autoantibodies ta
See all news about Transient neonatal myasthenia gravis

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How severe is my baby's condition, and will they need breathing support?,How long do you expect the symptoms to last in my baby's case?,Will my baby need medication, and if so, what are the side effects?,How will feeding be managed while my baby is recovering?,Are there any long-term effects I should watch for as my child grows?,If I have another pregnancy, what is the chance that the next baby will also be affected?,What warning signs should I watch for at home after discharge?

Common questions about Transient neonatal myasthenia gravis

What is Transient neonatal myasthenia gravis?

Transient neonatal myasthenia gravis (also called transient neonatal MG) is a temporary condition that affects newborn babies born to mothers who have myasthenia gravis. Myasthenia gravis is an autoimmune disease where the mother's immune system makes antibodies that attack the connections between nerves and muscles. During pregnancy, these antibodies can cross the placenta and enter the baby's bloodstream. After birth, these maternal antibodies cause the baby to have muscle weakness and difficulty with basic functions like feeding, breathing, and moving. The most common symptoms include a we

How is Transient neonatal myasthenia gravis inherited?

Transient neonatal myasthenia gravis follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Transient neonatal myasthenia gravis typically begin?

Typical onset of Transient neonatal myasthenia gravis is neonatal. Age of onset can vary across affected individuals.

Which specialists treat Transient neonatal myasthenia gravis?

15 specialists and care centers treating Transient neonatal myasthenia gravis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Transient neonatal myasthenia gravis?

5 patient support programs are currently tracked on UniteRare for Transient neonatal myasthenia gravis. See the treatments and support programs sections for copay assistance, eligibility, and contact details.